303 related articles for article (PubMed ID: 18791168)
21. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
22. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
23. Activation of CB
Joffre J; Yeh CC; Wong E; Thete M; Xu F; Zlatanova I; Lloyd E; Kobzik L; Legrand M; Hellman J
J Immunol; 2020 Jun; 204(12):3339-3350. PubMed ID: 32385136
[No Abstract] [Full Text] [Related]
24. Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells.
Yang L; Li FF; Han YC; Jia B; Ding Y
Mediators Inflamm; 2015; 2015():362126. PubMed ID: 25653478
[TBL] [Abstract][Full Text] [Related]
25. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2.
Kaplan BL; Ouyang Y; Rockwell CE; Rao GK; Kaminski NE
J Leukoc Biol; 2005 Jun; 77(6):966-74. PubMed ID: 15774549
[TBL] [Abstract][Full Text] [Related]
26. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production.
Shmist YA; Goncharov I; Eichler M; Shneyvays V; Isaac A; Vogel Z; Shainberg A
Mol Cell Biochem; 2006 Feb; 283(1-2):75-83. PubMed ID: 16444588
[TBL] [Abstract][Full Text] [Related]
27. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
28. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
[TBL] [Abstract][Full Text] [Related]
29. Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.
Sido JM; Nagarkatti PS; Nagarkatti M
J Leukoc Biol; 2015 Sep; 98(3):435-47. PubMed ID: 26034207
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
31. Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.
Henriquez JE; Crawford RB; Kaminski NE
Toxicol Appl Pharmacol; 2019 Apr; 369():82-89. PubMed ID: 30807757
[TBL] [Abstract][Full Text] [Related]
32. CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol.
Wasserman E; Tam J; Mechoulam R; Zimmer A; Maor G; Bab I
Ann N Y Acad Sci; 2015 Jan; 1335():110-9. PubMed ID: 25573322
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.
Braun A; Engel T; Aguilar-Pimentel JA; Zimmer A; Jakob T; Behrendt H; Mempel M
Immunobiology; 2011 Apr; 216(4):466-76. PubMed ID: 21056512
[TBL] [Abstract][Full Text] [Related]
34. Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.
Lombard C; Hegde VL; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2011 Nov; 339(2):607-17. PubMed ID: 21831965
[TBL] [Abstract][Full Text] [Related]
35. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice.
Baskfield CY; Martin BR; Wiley JL
J Pharmacol Exp Ther; 2004 Apr; 309(1):86-91. PubMed ID: 14718593
[TBL] [Abstract][Full Text] [Related]
37. Effect of delta9-tetrahydrocannabinol on in vitro sensitization of mouse splenic lymphocytes.
Lefkowitz SS; Klager K
Immunol Commun; 1978; 7(5):557-66. PubMed ID: 359460
[TBL] [Abstract][Full Text] [Related]
38. Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function.
Schatz AR; Koh WS; Kaminski NE
Immunopharmacology; 1993; 26(2):129-37. PubMed ID: 8282537
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses.
Basu S; Ray A; Dittel BN
J Immunol; 2011 Dec; 187(11):5720-32. PubMed ID: 22048769
[TBL] [Abstract][Full Text] [Related]
40. Suppression by Δ(9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation.
Ngaotepprutaram T; Kaplan BL; Carney S; Crawford R; Kaminski NE
Toxicology; 2013 Aug; 310():84-91. PubMed ID: 23727458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
